Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

GTBP

GT Biopharma Inc

Dec 13 • 04:00PM ET

2.75

Dollar change +0.01
Percentage change 0.36	%

Healthcare • Biotechnology • USA • NASD

Peers: LLY ABBV BMY AMGN MRK JNJ GILD REGN VRTX BIIB

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-7.48	Insider Own	12.15%	Shs Outstand	2.23M	Perf Week	7.00%
Market Cap	6.16M	Forward P/E	-	EPS next Y	-6.79	Insider Trans	0.00%	Shs Float	1.96M	Perf Month	-10.13%
Income	-12.35M	PEG	-	EPS next Q	-1.55	Inst Own	64.27%	Short Float	0.56%	Perf Quarter	30.33%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	12.81%	Short Ratio	0.50	Perf Half Y	-4.84%
Book/sh	0.94	P/B	2.93	EPS next Y	-	ROA	-107.82%	Short Interest	0.01M	Perf Year	-59.26%
Cash/sh	2.91	P/C	0.95	EPS next 5Y	-	ROE	-204.08%	52W Range	1.92 - 10.66	Perf YTD	-64.05%
Dividend Est.	-	P/FCF	-	EPS past 5Y	70.75%	ROI	-588.89%	52W High	-74.20%	Beta	0.62
Dividend TTM	-	Quick Ratio	1.45	Sales past 5Y	0.00%	Gross Margin	-	52W Low	43.22%	ATR (14)	0.32
Dividend Ex-Date	-	Current Ratio	1.45	EPS Y/Y TTM	12.50%	Oper. Margin	-	RSI (14)	47.60	Volatility	15.30% 11.51%
Employees	2	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	150.00
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	13.60%	Payout	-	Rel Volume	0.89	Prev Close	2.74
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	Oct 29	Avg Volume	22.09K	Price	2.75
SMA20	-4.09%	SMA50	-0.10%	SMA200	-10.15%	Trades		Volume	19,569	Change	0.36%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-02-24	Initiated	ROTH MKM	Buy	$11
May-24-21	Initiated	H.C. Wainwright	Buy	$25
Apr-13-21	Initiated	B. Riley Securities	Buy	$21
Mar-17-21	Initiated	ROTH Capital	Buy	$25

Nov-14-24 04:00PM	GT Biopharma Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Sep-26-24 09:15AM	GT Biopharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference (GlobeNewswire)
Sep-24-24 09:15AM	GT Biopharma to Host Virtual KOL Event Showcasing its NK Cell Engager Pipeline and Broad Indication Potential on October 10, 2024 (GlobeNewswire)
Aug-14-24 09:54PM	GTBP Stock Earnings: GT Biopharma Reported Results for Q2 2024 (InvestorPlace)
04:05PM	GT Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
09:15AM	Loading…
Jun-27-24 09:15AM	GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ Leukemia (GlobeNewswire) -7.08%
May-21-24 09:15AM	GT Biopharma, Inc. Announces $3.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) -28.21%
May-20-24 08:40AM	Why Is GT Biopharma (GTBP) Stock Up 143% Today? (InvestorPlace) +150.00%
07:36AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
May-16-24 10:53AM	GTBP Stock Earnings: GT Biopharma Beats EPS for Q1 2024 (InvestorPlace) +7.21%
May-15-24 05:00PM	GT Biopharma Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-26-24 09:53PM	GTBP Stock Earnings: GT Biopharma Beats EPS for Q4 2023 (InvestorPlace)
05:00PM	GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results (GlobeNewswire)
Feb-01-24 11:00AM	GT Biopharma, Inc. Announces 1-for-30 Reverse Stock Split (GlobeNewswire) -6.16%
Dec-06-23 09:30AM	Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend GT Biopharma Stockholders Vote FOR All Proposed Items at the Upcoming Special Meeting of Stockholders (GlobeNewswire)
09:30AM	Loading…
Dec-04-23 09:30AM	GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia (GlobeNewswire) +6.91%
Nov-06-23 09:30AM	GT Biopharma Presented Positive Preclinical Data for GTB-5550, a Novel TriKE Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting (GlobeNewswire)
Nov-01-23 09:00AM	GT Biopharma Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Aug-07-23 09:00AM	GT Biopharma Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-03-23 01:25PM	GT Biopharma to Participate in the H.C. Wainwright Immune Cell Engager Conference on August 17, 2023 (GlobeNewswire) -6.43%
May-15-23 05:00PM	GT Biopharma Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) +5.19%
May-04-23 09:05AM	GT Biopharma Names Charles J. Casamento to the Board of Directors (GlobeNewswire)
Apr-12-23 07:07AM	Daily Vickers Top Buyers & Sellers for 04/12/2023 (Argus Research) -5.79%
Mar-30-23 05:00PM	GT Biopharma Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire) +18.33%
Feb-24-23 09:00AM	GT Biopharma to Participate in the H.C. Wainwright Cell Therapy Virtual Conference (GlobeNewswire)
Feb-02-23 09:46AM	GT Biopharma Issues Open Letter to Shareholders Detailing Recent Activities (GlobeNewswire) +5.00%
Dec-30-22 08:00AM	GT Biopharma, Inc. Announces $6.5 Million Registered Direct Offering Priced At Premium To Market (GlobeNewswire) -8.69%
Dec-14-22 07:30AM	GT Biopharma Names Dr. Jeff Miller as Consulting Chief Medical Officer (GlobeNewswire) -6.67%
Dec-12-22 07:30AM	GT Biopharma and Fate Therapeutics Present Preclinical Data Highlighting Novel Dual Antigen Targeting Approach For The Treatment of AML at ASH 2022 (GlobeNewswire)
Nov-10-22 03:15PM	GT Biopharma Presents Two Posters at the Society for Immunotherapy of Cancers (SITC) 37th Annual Meeting (GlobeNewswire)
09:00AM	Loading…
Nov-03-22 09:00AM	GT Biopharma to Present New Data on Novel Dual-Antigen Targeting Approach Against AML at Upcoming 2022 ASH Annual Meeting (GlobeNewswire)
Oct-31-22 05:15PM	GT Biopharma Reports Third Quarter Fiscal 2022 Financial Results and Business Update (GlobeNewswire)
Oct-25-22 02:44PM	GT Biopharma Presents at LD Micro on October 26, 2022 at 4:30 pm PST (Newsfile)
Oct-06-22 08:18AM	GT Biopharma Announces Two Poster Presentations at the Society for Immunotherapy of Cancers (SITC) 37th Annual Meeting (GlobeNewswire)
Oct-04-22 04:10PM	GT Biopharma Announces Adjournment of Special Shareholders Meeting (GlobeNewswire)
Sep-12-22 09:34AM	GT Biopharma Poster Presentation and Mini Oral Session at ESMO Congress 2022 Demonstrates GTB-5550 TriKE® Ability to Specifically Target and Efficiently Kill Multiple B7H3+ Solid and Hematologic Malignancies (GlobeNewswire)
Sep-08-22 07:30AM	GT Biopharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference in September (GlobeNewswire) +12.75%
Aug-30-22 06:00PM	GT Biopharma Affirms Manufacturing Timeline For Lead Investigational Asset GTB-3650 (GlobeNewswire)
Aug-11-22 09:35AM	GT Biopharma Reports Second Quarter Fiscal 2022 Financial Results and Business Update (GlobeNewswire) -9.41%
Jun-10-22 08:00AM	GT Biopharma Presents Preclinical Data Demonstrating Second-Generation CD19 Targeting Tri-Specific Killer Engager (TriKE®) Driving Robust NK Cell Function Against B Cell Malignancies at EHA 2022 Congress (GlobeNewswire) -5.21%
May-19-22 07:45AM	Will GT Biopharma (NASDAQ:GTBP) Spend Its Cash Wisely? (Simply Wall St.) +5.56%
May-16-22 08:01AM	GT Biopharma Reports First Quarter Fiscal 2022 Financial Results and Business Update (GlobeNewswire) +6.74%
May-12-22 08:00AM	GT Biopharma to Participate at H.C. Wainwright Hybrid Global Investment Conference (GlobeNewswire) +5.26%
Apr-11-22 07:30AM	GT Biopharma Presents Preclinical Data Demonstrating Novel B7H3+ Tumor Targeting GTB-5550 TriKE® Driving NK Cell Activation and ADCC Against Head and Neck Squamous Cell Carcinomas at AACR Annual Meeting 2022 (GlobeNewswire)
Mar-28-22 04:15PM	GT Biopharma Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update (PR Newswire) +7.04%
Mar-21-22 07:30AM	GT Biopharma Presents TriKE® Nanobody Pipeline (GTB-5550) Preclinical Multiple Myeloma Proof-of-Concept Data at 2022 EBMT Annual Meeting (PR Newswire)
Mar-09-22 04:24PM	GT Biopharma Presented Preclinical Data Demonstrating Novel Mesothelin-Targeted TriKE® Driving Cytotoxicity Across All Stages of Non-Small Cell Lung Cancer at ESMO TAT 2022 (PR Newswire) +9.63%
Mar-03-22 07:30AM	GT Biopharma to Participate In-Person at 34th Annual ROTH Conference, March 13-15, 2022 (PR Newswire)
Feb-24-22 07:30AM	GT Biopharma to Present Pre-Clinical Data at Upcoming Medical Conferences (PR Newswire) +12.86%
Feb-18-22 07:30AM	GT Biopharma Appoints Manu Ohri as Chief Financial Officer (PR Newswire) -10.98%
Jan-20-22 07:30AM	GT Biopharma to Present at B. Riley Securities' Virtual Oncology Conference (PR Newswire)
Jan-06-22 04:30PM	GT Biopharma Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +7.74%
Jan-04-22 05:38PM	Silverleafe Capital Partners, LLC Buys Amazon. ... (GuruFocus.com) -5.96%
Dec-08-21 07:30AM	GT Biopharma Demonstrates Novel B7-H3 Targeting Dual Camelid Nanobody BiKE and GTB-5550 Induce NK Cell Activation Against Broad Spectrum of Tumors at ESMO IO Congress 2021 (PR Newswire)
Nov-30-21 07:30AM	GT Biopharma Abstract on Novel B7-H3 Immune Checkpoint Targeting Broad Spectrum Solid and Hematologic Malignancies Accepted for Presentation at ESMO IO Congress 2021 (PR Newswire)
Nov-24-21 04:05PM	GT BioPharma to Host a Management Update Conference Call (PR Newswire)
Nov-17-21 07:28AM	We Think GT Biopharma (NASDAQ:GTBP) Can Afford To Drive Business Growth (Simply Wall St.)
Nov-10-21 04:10PM	GT BioPharma Reports Third Quarter 2021 Financial Results and Provides Corporate Update (PR Newswire)
Nov-08-21 07:30AM	GT Biopharma Announces Executive Leadership Transition to Implement Next Phase of Strategic Journey (PR Newswire) -19.28%
Oct-07-21 10:00AM	OXIS International Inc. (GTBP) Loses 32.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) +5.14%
Sep-20-21 07:00AM	GT BioPharma's Next Generation Camelid TriKE® Nanobody Platform Highlighted at ESMO Congress 2021 (PR Newswire) -5.78%
Sep-16-21 12:00PM	OXIS International Inc. (GTBP) Moves to Buy: Rationale Behind the Upgrade (Zacks)
Sep-15-21 07:00AM	GT Biopharma Announces Updated Positive Safety Data From Phase 1 GTB-3550 Monotherapy TriKE Trial an Investigational Immunotherapy for Refractory Cancers to be Presented at ESMO Congress 2021 (PR Newswire)
Sep-13-21 07:00AM	GT Biopharma Advances GTB-3650, a Second-Generation Tri-Specific Killer Engager -TriKE®, Into IND-Enabling Studies (PR Newswire)
Sep-09-21 07:00AM	GT Biopharma Announces Issuance of Two New Patents Covering TriKE® Platform Technologies (PR Newswire)
Sep-08-21 12:28PM	GT Biopharma to Present at Upcoming September Investor Conferences (PR Newswire)
Aug-23-21 07:00AM	GT Biopharma Announces the Promotion of Dr. Gregory Berk to President of Research & Development and Chief Medical Officer (PR Newswire)
Aug-13-21 07:30AM	GT Biopharma Provides Second Quarter 2021 Business Update (PR Newswire) -7.40%
Aug-06-21 08:00AM	GT Biopharma to Host Conference Call to Discuss Second Quarter 2021 Results (PR Newswire)
Aug-03-21 07:00AM	GT Biopharma Announces Positive Preclinical Results For GTB-5550 B7H3 TriKE (PR Newswire)
Jul-28-21 08:00AM	GT Biopharma Announces $16 million in Warrant Exercise Proceeds (PR Newswire) +6.09%
Jul-16-21 03:13AM	Is GT Biopharma, Inc. (NASDAQ:GTBP) Popular Amongst Insiders? (Simply Wall St.)
Jul-07-21 08:00AM	GT Biopharma Announces Sponsored Research Agreement With Dr. Jeffrey S. Miller Of The University Of Minnesota (PR Newswire)
Jun-24-21 08:00AM	GT Biopharma CEO, Tony Cataldo to Present at Sir Anthony Ritossa's Global Family Office Investment Summit (PR Newswire) -6.42%
Jun-23-21 08:00AM	GT Biopharma Announces Interim GTB-3550 Trike Monotherapy Clinical Trial Results At 2021 Raymond James Human Health Innovation Conference (PR Newswire)
Jun-21-21 08:00AM	Dr. Jeffrey S. Miller to Present on Progress of GTB-3550 TriKE Phase I Trial Accompanying GT Biopharma's Company Presentation at Raymond James Human Health Innovation Conference (PR Newswire) -7.73%
Jun-16-21 08:00AM	GT Biopharma to Present at Raymond James Human Health Innovation Conference (PR Newswire)
Jun-08-21 08:00AM	GT Biopharma to be Added to the Russell 2000® Index (PR Newswire)
May-18-21 09:50AM	GT Biopharma to Host Interim GTB-3550 TriKE Data Review Call with Dr. Jeffrey S. Miller on May 19, 2021 at 4:00 PM ET (PR Newswire) +5.12%
May-17-21 06:54PM	GT Biopharma Reports First Quarter 2021 Results (PR Newswire)
May-12-21 07:00AM	GT Biopharma Announces Update On The Commencement Of The GTB-3550 TriKE Monotherapy Phase 2 Clinical Trial And Solid Tumor TriKE Product Candidates (PR Newswire) -14.37%
Apr-26-21 07:00AM	GT Biopharma Announces the Appointments of Gregory Berk, M.D. to Chief Medical Officer and Jeffrey S. Miller, M.D. to Consulting Chief Scientific Officer (PR Newswire)
Apr-19-21 07:00AM	GT Biopharma Reports Fourth Quarter and Year End 2020 Results and Business Update (PR Newswire) -6.50%
Apr-12-21 08:00AM	GT Biopharma Announces GTB-3550 TriKE Monotherapy Rescues and Restores NK Cell Immune Surveillance in Relapsed/Refractory AML and MDS Cancer Patients (PR Newswire)
Apr-08-21 08:00AM	GT Biopharma Announces Enrollment Of Patient 10 in GTB-3550 TriKE Phase I/II Clinical Trial (PR Newswire) -9.75%
Mar-29-21 07:00AM	GT Biopharma's TriKE Interim Clinical Trial Results Presented At Innate Killer Summit 2021 (PR Newswire)
Mar-17-21 08:00AM	GT Biopharma Announces Updated Interim GTB-3550 Trike Clinical Trial Results (PR Newswire)
Mar-10-21 08:00AM	GT Biopharma to Present at The Virtual 33rd Annual Roth Conference (PR Newswire)
Mar-08-21 08:30AM	GT Biopharma Announces Preclinical Results For Its ROR1 TriKE As A Treatment For Prostate Cancer (PR Newswire) -7.35%
Mar-04-21 08:30AM	GT Biopharma Adds University of Wisconsin--Madison Carbone Cancer Center as Second Site in Ongoing Phase 1/2 Clinical Trial of GTB-3550 TriKE, a Novel NK Cell Therapeutic Cancer Treatment (PR Newswire) -11.82%
Mar-02-21 03:00AM	Psyched Wellness Provides Update on Pre-Clinical Trial of Its Muscimol Extract AME-1 (Newsfile)
Feb-18-21 08:00AM	GT Biopharma Transfers TriKE Manufacturing To Cytovance Biologics In Preparation For Expanded And Multiple Liquid And Solid Tumor Clinical Trials (PR Newswire)
Feb-16-21 08:00AM	GT Biopharma Announces Closing of $23.7 Million Public Offering (Business Wire) +13.64%
Feb-11-21 08:00AM	GT Biopharma Announces Pricing of $23,650,000 Public Offering and Uplisting to The Nasdaq Capital Market (Business Wire) -39.06%
Jan-19-21 09:00AM	GT Biopharma Appoints Two New Independent Directors (PR Newswire) -14.43%
Jan-12-21 10:00AM	GT Biopharma Announces Eighth Patient Begins Treatment Of GTB-3550 (PR Newswire)
Jan-04-21 09:45AM	GT Biopharma (OTCQB: GTBP) Announces Corporate Update Conference Call (PR Newswire)
Dec-28-20 09:35AM	GT Biopharma Announces TriKE For The Treatment Of Breast And GI Cancers (PR Newswire)
Dec-21-20 11:00AM	GT BIOPHARMA ANNOUNCES FDA DATA - GTB-3550 TriKE REDUCES CANCER CELLS BY 61.7% FOR A HIGH-RISK MYELODYSPLASTIC SYNDROMES (HR-MDS) PATIENT (PR Newswire) +12.58%
Dec-17-20 09:15AM	GT Biopharma And Cytovance Biologics Announce Milestone Achievement (PR Newswire) +5.08%

GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of the immuno-oncology therapeutic products based proprietary TriKE NK cell engager platform. The TriKE platform is designed to harness and enhance the cancer killing abilities of a patient's immune system natural killer cells (NK cells). Its product, GTB-3550, is initially developed for the treatment of AML and MDS, and other CD33+ hematologic cancers. GT Biopharma has a worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology. The company was founded in 1965 and is headquartered in San Francisco, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GTBP

GT Biopharma Inc

Upgrade your FINVIZ experience